Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.
By J. Kiladjian, B. Cassinat, S. Chevret, P. Turlure, N. Cambier, M. Roussel, S. Bellucci, B. Grandchamp, C. Chomienne, P. Fenaux. Blood, 2008
601 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/6bf55656bf2bb16c6f15bface41bf7857487d99a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- F. Cervantes
- A. Tefferi
- A. Pardanani
- T. Barbui
- G. Finazzi
- G. Barosi
- R. Hehlmann
- G. Birgegard
Citations in the corpus
- Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. (2011, methodology): “Pegylated IFNhas been demonstrated in phase II trials of patients with PV to have clinical efficacy as measured by normalization of myeloproliferation, lack of vascular events while on therapy, and a decrease in the JAK2V617F allele burden.(32) All patients with PV should be managed with phlebotomy ”